1. Scrip

Progress Or Hype? A Decade Of Cell Therapy In Japan

Mixed Commercial Success

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

After ten years of promising investment for cell therapy, Japan has cautiously reviewing its policies.
commercial cell therapy success elusive in Japan despite supportive policies • Source: Shutterstock

Some 10 years since Japan introduced policies, regulations and review pathways to encourage the development and commercialization of cell therapy products, the country has recently modified some regulations in the field to take account of an admitted “lack of predictability” for some products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia